ResMed Inc (RMD)vsShell PLC ADR (SHEL)
RMD
ResMed Inc
$206.76
-0.06%
HEALTHCARE · Cap: $30.01B
SHEL
Shell PLC ADR
$83.97
-0.32%
ENERGY · Cap: $243.12B
Smart Verdict
WallStSmart Research — data-driven comparison
Shell PLC ADR generates 4719% more annual revenue ($266.89B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 6.7%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 73/100 (B).
RMD
Strong Buy73
out of 100
Grade: B
SHEL
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.1%
Fair Value
$229.58
Current Price
$206.76
$22.82 premium
Margin of Safety
+4.5%
Fair Value
$84.58
Current Price
$83.97
$0.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
Mega-cap, among the largest globally
Reasonable price relative to book value
Earnings expanding 376.2% YoY
Attractively priced relative to earnings
Generating 1.6B in free cash flow
Areas to Watch
No major concerns identified
6.7% margin — thin
Weak financial health signals
Revenue declined 3.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bull Case : SHEL
The strongest argument for SHEL centers on Market Cap, Price/Book, EPS Growth. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : SHEL
The primary concerns for SHEL are Profit Margin, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
RMD profiles as a mature stock while SHEL is a value play — different risk/reward profiles.
RMD carries more volatility with a beta of 0.84 — expect wider price swings.
RMD is growing revenue faster at 10.8% — sustainability is the question.
SHEL generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
RMD scores higher overall (73/100 vs 61/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Shell PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
Shell plc is a global petrochemical and energy company. The company is headquartered in The Hague, the Netherlands.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?